By AVCJ Larissa Ku
CDH Investments and Huaxing Healthcare Fund have led a USD 120m Series B for InnoRNA, a China-based mRNA drug developer. Existing investors CPE and Fangyuan Capital re-upped.
The company was founded in 2019 by Linxian Li, a specialist in lipid nanoparticle (LNP) technology. LNP is a carrier vehicle that protects mRNA from degradation and aids intracellular delivery and endosomal escape.
The Series B proceeds will go towards the R&D into mRNA-based drugs and vaccines and the exploration of untapped therapeutic areas.
Most vaccines insert a weakened or inactive germ into the body to trigger an immune response, producing antibodies, which in turn prevent infection. In contrast, mRNA teaches cells to make proteins that trigger immune responses. However, mRNA cannot enter the cell nucleus and it is easily degraded.
Read More: https://www.avcj.com/avcj/news/3026542/cdh-huaxing-lead-usd120m-series-b-for-china-s-innorna
By AVCJ Larissa Ku
CDH Investments and Huaxing Healthcare Fund have led a USD 120m Series B for InnoRNA, a China-based mRNA drug developer. Existing investors CPE and Fangyuan Capital re-upped.
The company was founded in 2019 by Linxian Li, a specialist in lipid nanoparticle (LNP) technology. LNP is a carrier vehicle that protects mRNA from degradation and aids intracellular delivery and endosomal escape.
The Series B proceeds will go towards the R&D into mRNA-based drugs and vaccines and the exploration of untapped therapeutic areas.
Most vaccines insert a weakened or inactive germ into the body to trigger an immune response, producing antibodies, which in turn prevent infection. In contrast, mRNA teaches cells to make proteins that trigger immune responses. However, mRNA cannot enter the cell nucleus and it is easily degraded.
Read More: https://www.avcj.com/avcj/news/3026542/cdh-huaxing-lead-usd120m-series-b-for-china-s-innorna